This review is intended to reflect upon the current status and perspectives of cell-based
immunotherapy at a time when the promise of extensive pre-clinical research has been
translated into encouraging clinical responses. However, some of these have also been
complicated by significant adverse reactions. As the field moves towards definitive late stage
trials, with a growing interest from pharmaceutical companies, we realize that novel cell
therapy strategies pose questions that are familiar to traditional drug development, along …